Page 9 - Slides

Population-Based Study on the Association of PSADT

With MFS and OS in nmCRPC 1

Low risk
PSADT > 10 mos

n = 243
Men with Received
index PC medical

from the and/or High risk
OPTUM CRPC* nmCRPC † PSADT ≤ 10 mos
claims surgical n = 1259 n = 504 n = 150
database castration 2

2007-2017
n = 84,479 n = 15,431 Unknown risk ‡

n = 111

• ~30% of CRPC patients had a PSADT ≤ 10 mos

*Using Prostate Cancer Working Group 2 criteria; 3 † Patients received
continuous androgen deprivation therapy (ADT) coverage as in the
phase 3 SPARTAN trial; Nonevaluable PSADT due to inadequate
4 ‡
prostate-specific antigen (PSA) lab values
ADT = Androgen-deprivation therapy; MFS = Metastasis-free survival; OS = 1. Saad F, et al. AUA 2018 (Abstr PD10-04); 2. Alemayehu B, et al. J Med Econ 2010;13:351-61;
Overall survival; PSADT = PSA doubling time 3. Scher HI, et al. J Clin Oncol 2008;26:1148-59; 4. Smith MR, et al. N Engl J Med. 2018;378:1408-18